{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:24:55Z","timestamp":1789586695847,"version":"build-2803163510"},"reference-count":21,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Currently, some monoclonal antibodies (mAbs) are being studied for chronic rhinosinusitis with nasal polyps (CRSwNP). Three anti-IL-5 mAb: mepolizumab, reslizumab and benralizumab, have been tested through randomized clinical trials. In this real-life study, we aimed to describe the nasal effects of a cohort of asthmatic adults treated with anti-IL-5 mAb. Methods: We carried out an observational study in adults (\u226518 years) on anti-IL-5 mAb treatment. Variables included ACT and SNOT\u221222 questionnaires, nasal polyps score, blood total IgE levels and blood eosinophil count. Results: Overall, 38 participants were included in the study; 19 patients received mepolizumab, 17 were treated with benralizumab and 2 patients were given reslizumab. There was a statistically significant difference in the ACT and SNOT\u221222 scores before and after mAb treatment. ACT score increased from 11.05 to 21.5 after treatment (p &lt; 0.001). SNOT\u221222 decreased from 57 to 37.3 after treatment (p = 0.004). No statistically significant differences between mAb groups were observed regarding the ACT or the SNOT\u221222 (p = 0.775) response (p = 0.775). In addition, 60.53% of patients obtained a minimal clinically important difference (MCID) in SNOT\u221222. Conclusions: A significant clinical response based on SNOT\u221222 score evolution after anti-IL-5 mAb treatment was observed. This study also demonstrated that blood eosinophil count, rather than serum total IgE levels, is the best predictor of asthma symptom improvement, which was assessed through the ACT and SNOT\u221222 questionnaires.<\/jats:p>","DOI":"10.3390\/jcm11237056","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T07:10:27Z","timestamp":1669792227000},"page":"7056","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Nasal Symptoms in Asthmatic Patients under Treatment with Anti-IL-5 Monoclonal Antibodies. A Real-Life Cohort Study"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3588-9095","authenticated-orcid":false,"given":"Juan","family":"Maza-Solano","sequence":"first","affiliation":[{"name":"Rhinology Study Group, Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS), 13005 Paris, France"},{"name":"Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, Virgen Macarena University Hospital, 41003 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Calvo-Henr\u00edquez","sequence":"additional","affiliation":[{"name":"Rhinology Study Group, Young-Otolaryngologists of the International Federations of Oto-Rhino-Laryngological Societies (YO-IFOS), 13005 Paris, France"},{"name":"Service of Otolaryngology, Rhinology Unit, Hospital Complex of Santiago de Compostela, 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isam","family":"Alobid","sequence":"additional","affiliation":[{"name":"Rhinology and Skull Base Unit, ENT Department, Hospital Cl\u00ednic, Instituto de Investigaciones Biom\u00e9dicas August Pi i Sunyer (IDIBAPS), CIPERES, Barcelona University, 08007 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"\u00c1lvarez-Cendrero","sequence":"additional","affiliation":[{"name":"Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, Virgen Macarena University Hospital, 41003 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4516-0369","authenticated-orcid":false,"given":"\u00d3scar","family":"Palomares","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0640-0550","authenticated-orcid":false,"given":"Ram\u00f3n","family":"Moreno-Luna","sequence":"additional","affiliation":[{"name":"Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, Virgen Macarena University Hospital, 41003 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0423-9241","authenticated-orcid":false,"given":"Jaime","family":"Santos-Perez","sequence":"additional","affiliation":[{"name":"Service of Otolaryngology, Rhinology Unit, University Hospital of Valladolid, 47005 Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5193-3869","authenticated-orcid":false,"given":"Jaime","family":"Gonz\u00e1lez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, Virgen Macarena University Hospital, 41003 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5897-7821","authenticated-orcid":false,"given":"Seraf\u00edn","family":"S\u00e1nchez-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, Virgen Macarena University Hospital, 41003 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"SEAIC-SEORL. Consensus Document on Nasal Polyposis. POLINA Project","volume":"21","author":"Alobid","year":"2011","journal-title":"J. Investig. Allergol Clin. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4193\/Rhin17.156","article-title":"Monoclonal Antibodies for the Treatment of Chronic Rhinosinusitis with Nasal Polyposis: A Systematic Review","volume":"56","author":"Tsetsos","year":"2018","journal-title":"Rhinology"},{"key":"ref_4","first-page":"145","article-title":"Eosinophilic Nasal Polyps Are a Rich Source of Eotaxin, Eotaxin-2 and Eotaxin-3","volume":"44","author":"Olze","year":"2006","journal-title":"Rhinology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and Safety of Benralizumab in Chronic Rhinosinusitis with Nasal Polyps: A Randomized, Placebo-Controlled Trial","volume":"149","author":"Bachert","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_6","first-page":"552","article-title":"Multi-Institutional Minimal Clinically Important Difference of the 22-Item Sinonasal Outcome Test in Medically Managed Chronic Rhinosinusitis","volume":"59","author":"Phillips","year":"2021","journal-title":"Rhinology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/alr.22774","article-title":"Benefits of Biologic Therapy Administered for Asthma on Co-Existent Chronic Rhinosinusitis: A Real-World Study","volume":"11","author":"Bajpai","year":"2021","journal-title":"Int. Forum. Allergy Rhinol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Han, J., Bachert, C., Fokkens, W., Desrosiers, M., Wagenmann, M., Lee, S., Smith, S., Martin, N., Mayer, B., and Yancey, S. (2021). Mepolizumab for Chronic Rhinosinusitis with Nasal Polyps (SYNAPSE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet Respir. Med., 9.","DOI":"10.1016\/S2213-2600(21)00097-7"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/alr.22101","article-title":"SNOT-22-Based Clusters in Chronic Rhinosinusitis without Nasal Polyposis Exhibit Distinct Endotypic and Prognostic Differences","volume":"8","author":"Lal","year":"2018","journal-title":"Int. Forum. Allergy Rhinol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1111\/all.14809","article-title":"Efficacy and Safety of Treatment with Biologicals for Severe Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review for the EAACI Guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 Levels Determine the Response to Anti-IL-5 Treatment in Patients with Nasal Polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and Safety of Benralizumab for Patients with Severe Asthma Uncontrolled with High-Dosage Inhaled Corticosteroids and Long-Acting \u03922-Agonists (SIROCCO): A Randomised, Multicentre, Placebo-Controlled Phase 3 Trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an Anti-Interleukin-5 Receptor \u03b1 Monoclonal Antibody, as Add-on Treatment for Patients with Severe, Uncontrolled, Eosinophilic Asthma (CALIMA): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"ref_14","unstructured":"(2021, December 06). EUFOREA Consensus on Biologics for CRSwNP with or without Asthma\u2014PubMed, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/31090937\/."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced Need for Surgery in Severe Nasal Polyposis with Mepolizumab: Randomized Trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a Humanized Anti-IL-5 MAb, as a Treatment Option for Severe Nasal Polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/cea.13696","article-title":"Obesity Influences the Outcomes of Anti-IgE (Omalizumab) Therapy of Asthma","volume":"50","author":"Gu","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejim.2018.01.026","article-title":"Factors Reducing Omalizumab Response in Severe Asthma","volume":"52","author":"Sposato","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-World Effectiveness and the Characteristics of a \u201cSuper-Responder\u201d to Mepolizumab in Severe Eosinophilic Asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-Adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/1945892420972326","article-title":"Effects of Omalizumab Treatment in Patients With Recalcitrant Nasal Polyposis and Mild Asthma: A Multicenter Retrospective Study","volume":"35","year":"2021","journal-title":"Am. J. Rhinol. Allergy"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/23\/7056\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:29:08Z","timestamp":1760146148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/23\/7056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":21,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["jcm11237056"],"URL":"https:\/\/doi.org\/10.3390\/jcm11237056","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]}}}